Edition:
United Kingdom

Acorda Therapeutics Inc (ACOR.OQ)

ACOR.OQ on NASDAQ Stock Exchange Global Select Market

10.16USD
24 May 2019
Change (% chg)

$-0.12 (-1.17%)
Prev Close
$10.28
Open
$10.35
Day's High
$10.49
Day's Low
$9.82
Volume
281,893
Avg. Vol
275,215
52-wk High
$36.25
52-wk Low
$9.67

Latest Key Developments (Source: Significant Developments)

Acorda Therapeutics Reports Q1 Non-GAAP Loss Per Share Of $0.56
Thursday, 2 May 2019 

May 2 (Reuters) - Acorda Therapeutics Inc ::ACORDA PROVIDES UPDATE FOR FIRST QUARTER ENDED MARCH 31, 2019.Q1 NON-GAAP LOSS PER SHARE $0.56.Q1 GAAP LOSS PER SHARE $1.00.Q1 EARNINGS PER SHARE ESTIMATE $-0.94 -- REFINITIV IBES DATA.FOR QUARTER ENDED MARCH 31, 2019, REPORTED AMPYRA NET REVENUE OF $40.1 MILLION COMPARED TO $102.8 MILLION.EXPECTS AMPYRA REVENUE TO CONTINUE TO DECLINE.ACORDA - WILL NO LONGER PROVIDE REVENUE GUIDANCE FOR AMPYRA, DUE TO UNPREDICTABLE TRAJECTORY OF REVENUE DECLINE GIVEN ENTRANCE OF GENERICS.RESEARCH AND DEVELOPMENT EXPENSES FOR FULL YEAR 2019 ARE EXPECTED TO BE $70-$80 MILLION.SG&A EXPENSES FOR FULL YEAR 2019 ARE EXPECTED TO BE $200-$210 MILLION.ACORDA THERAPEUTICS - QTRLY TOTAL REVENUE $44.1 MILLION VERSUS $106.2 MILLION.Q1 REVENUE VIEW $33.0 MILLION -- REFINITIV IBES DATA.  Full Article

Acorda Therapeutics Announces FDA Approval Of Inbrija
Monday, 24 Dec 2018 

Dec 24 (Reuters) - Acorda Therapeutics Inc ::ACORDA THERAPEUTICS ANNOUNCES FDA APPROVAL OF INBRIJA™ (LEVODOPA INHALATION POWDER).  Full Article

Grünenthal Acquires Global Rights For Qutenza
Monday, 5 Nov 2018 

Nov 5 (Reuters) - Acorda Therapeutics Inc ::GRÜNENTHAL ACQUIRES GLOBAL RIGHTS FOR QUTENZA®.GRÜNENTHAL GROUP - ACQUIRED ADDITIONAL GLOBAL COMMERCIAL RIGHTS FOR DERMAL PAIN PATCH QUTENZA (8% CAPSAICIN) FROM ACORDA THERAPEUTICS.  Full Article

Acorda Therapeutics Q3 GAAP Loss Per Share Of $0.29
Wednesday, 31 Oct 2018 

Oct 31 (Reuters) - Acorda Therapeutics Inc ::ACORDA PROVIDES FINANCIAL AND PIPELINE UPDATE FOR THIRD QUARTER 2018.Q3 REVENUE $142.8 MILLION .Q3 GAAP LOSS PER SHARE $0.29.Q3 NON-GAAP EARNINGS PER SHARE $0.17.Q3 EARNINGS PER SHARE VIEW $-0.02 -- THOMSON REUTERS I/B/E/S.Q3 REVENUE VIEW $82.8 MILLION -- THOMSON REUTERS I/B/E/S.2018 NET REVENUE GUIDANCE INCREASED FROM $330-$350 MILLION TO MORE THAN $400 MILLION.CASH BALANCE FOR YEAR-END 2018 REVISED FROM MORE THAN $300 MILLION TO MORE THAN $400 MILLION.ACORDA THERAPEUTICS - AT SEPT 30, CO HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $460.9 MILLION.SEES AMPYRA 2018 NET REVENUE MORE THAN $400 MILLION.ACORDA THERAPEUTICS - SEES 2018 RESEARCH AND DEVELOPMENT EXPENSES TO BE $100-$110 MILLION INCLUDING PRE-LAUNCH MANUFACTURING EXPENSES ASSOCIATED WITH INBRIJA.  Full Article

Acorda Provides Financial And Pipeline Update For Q3 2018
Wednesday, 31 Oct 2018 

Oct 31 (Reuters) - Acorda Therapeutics Inc ::ACORDA PROVIDES FINANCIAL AND PIPELINE UPDATE FOR THIRD QUARTER 2018.Q3 GAAP LOSS PER SHARE $0.29.Q3 NON-GAAP EARNINGS PER SHARE $0.17.Q3 REVENUE $138 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.02 -- THOMSON REUTERS I/B/E/S.Q3 REVENUE VIEW $82.8 MILLION -- THOMSON REUTERS I/B/E/S.2018 NET REVENUE GUIDANCE INCREASED FROM $330-$350 MILLION TO MORE THAN $400 MILLION.CASH BALANCE FOR YEAR-END 2018 REVISED FROM MORE THAN $300 MILLION TO MORE THAN $400 MILLION.ACORDA THERAPEUTICS - AT SEPT 30, CO HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $460.9 MILLION.SEES AMPYRA 2018 NET REVENUE MORE THAN $400 MILLION.ACORDA THERAPEUTICS - SEES 2018 RESEARCH AND DEVELOPMENT EXPENSES TO BE $100-$110 MILLION INCLUDING PRE-LAUNCH MANUFACTURING EXPENSES ASSOCIATED WITH INBRIJA.  Full Article

Acorda Therapeutics Announces U.S. Federal Court Upholds Decision To Invalidate Ampyra Patents
Monday, 10 Sep 2018 

Sept 10 (Reuters) - Acorda Therapeutics Inc ::U.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT UPHOLDS DISTRICT COURT’S DECISION TO INVALIDATE AMPYRA® (DALFAMPRIDINE) PATENTS.ACORDA THERAPEUTICS - U.S. COURT OF APPEALS FOR FEDERAL CIRCUIT, BY A 2-1 VOTE, HAS UPHELD U.S. COURT'S DECISION TO INVALIDATE FOUR AMPYRA PATENTS.  Full Article

Acorda Announces FDA Acceptance Of New Drug Application For Inbrija
Tuesday, 20 Feb 2018 

Feb 20 (Reuters) - Acorda Therapeutics Inc ::ACORDA ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR INBRIJA™ (LEVODOPA INHALATION POWDER).ACORDA THERAPEUTICS INC - UNDER PRESCRIPTION DRUG USER FEE ACT (PDUFA), FDA HAS SET A TARGET DATE OF OCTOBER 5, 2018 FOR INBRIJA.  Full Article

Acorda Therapeutics Q4 Adj Shr $0.61
Thursday, 15 Feb 2018 

Feb 15 (Reuters) - Acorda Therapeutics Inc ::Q4 REVENUE $188.4 MILLION.Q4 NON-GAAP EARNINGS PER SHARE $0.61.Q4 GAAP LOSS PER SHARE $3.70.AMPYRA NET REVENUE IS EXPECTED TO BE $330 MILLION TO $350 MILLION IN 2018.RESEARCH AND DEVELOPMENT EXPENSES FOR FULL YEAR 2018 ARE EXPECTED TO BE $100 MILLION TO $110 MILLION.  Full Article

Acorda Therapeutics Sees FY 2018 Sales $330 Mln To $350 Mln For AMPYRA
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Acorda Therapeutics Inc ::ACORDA ANNOUNCES 2017 AMPYRA NET SALES AND PROVIDES 2018 FINANCIAL GUIDANCE AT J.P. MORGAN HEALTHCARE CONFERENCE.SEES FY 2018 SALES $330 MILLION TO $350 MILLION FOR AMPYRA.INBRIJA NDA RESUBMITTED IN DECEMBER 2017; INITIAL FDA RESPONSE EXPECTED IN FEBRUARY 2018.YEAR-END CASH BALANCE FOR 2018 IS PROJECTED TO BE OVER $300 MILLION.  Full Article

Acorda Therapeutics Is Exploring A Potential Sale - WSJ, Citing Sources
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Acorda Therapeutics Inc ::ACORDA THERAPEUTICS IS EXPLORING A POTENTIAL SALE - WSJ, CITING SOURCES.  Full Article